

# Afsaneh Alavi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7741666/publications.pdf>

Version: 2024-02-01

161  
papers

4,836  
citations

117453

34  
h-index

118652

62  
g-index

189  
all docs

189  
docs citations

189  
times ranked

3568  
citing authors

#	ARTICLE	IF	CITATIONS
1	Vacuoles, <sc>E1</sc> enzyme, Xâ€linked, autoinflammatory, somatic (<sc>VEXAS</sc>) syndrome: a presentation of two cases with dermatologic findings. International Journal of Dermatology, 2023, 62, .	0.5	8
2	Comorbidity screening in hidradenitis suppurativa: Evidence-based recommendations from the US and Canadian Hidradenitis Suppurativa Foundations. Journal of the American Academy of Dermatology, 2022, 86, 1092-1101.	0.6	77
3	Incidence, prevalence, and predictors of inflammatory arthritis in patients with hidradenitis suppurativa: a systematic review and metaâ€analysis. International Journal of Dermatology, 2022, 61, 1069-1079.	0.5	3
4	Biologic Use in Pediatric Patients With Hidradenitis Suppurativa: A Systematic Review. Journal of Cutaneous Medicine and Surgery, 2022, 26, 176-180.	0.6	5
5	International Dermatology Outcome Measures (IDEOM): Report from the 2020 Annual Meeting. Dermatology, 2022, 238, 430-437.	0.9	4
6	Use of thermal imaging and a dedicated woundâ€imaging smartphone app as an adjunct to staging hidradenitis suppurativa. British Journal of Dermatology, 2022, 186, 723-726.	1.4	5
7	Medical Management of Hidradenitis Suppurativa with Non-Biologic Therapy: Whatâ€™s New?. American Journal of Clinical Dermatology, 2022, 23, 167-176.	3.3	6
8	Lifestyle modifications and complementary treatments for hidradenitis suppurativa. Dermatological Reviews, 2022, 3, 126-136.	0.3	0
9	Janus kinase 1 inhibitor <sc>INCB054707</sc> for patients with moderateâ€toâ€severe hidradenitis suppurativa: results from two phase <sc>II</sc> studies*. British Journal of Dermatology, 2022, 186, 803-813.	1.4	44
10	Cutaneous manifestations of hospitalized <sc>COVID</sc> â€19 patients in the <sc>VIRUS COVID</sc> â€19 registry. International Journal of Dermatology, 2022, , .	0.5	1
11	Real-World Moderate-to-Severe Hidradenitis Suppurativa: Decrease in Disease Burden With Adalimumab. Journal of Cutaneous Medicine and Surgery, 2022, , 120347542210885.	0.6	1
12	Candida Infection Associated with Anti-IL-17 Medication: A Systematic Analysis and Review of the Literature. American Journal of Clinical Dermatology, 2022, 23, 469-480.	3.3	5
13	Comorbid diseases of Hidradenitis Suppurativa: a <sc>15â€Year Populationâ€Based</sc> study in Olmsted County, Minnesota, <sc>USA</sc>. International Journal of Dermatology, 2022, , .	0.5	6
14	Authorâ€™s Reply to Pestana et al. Comment on: â€œIs There a Role for Therapeutic Drug Monitoring in Patients with Hidradenitis Suppurativa on Tumor Necrosis Factor-Î± Inhibitors?â€ American Journal of Clinical Dermatology, 2022, 23, 593-594.	3.3	1
15	Get It Off Your Chest: A Narrative Review of Breast Ulcers. Advances in Skin and Wound Care, 2022, 35, 306-313.	0.5	0
16	Combining medical and surgical management strategies for hidradenitis suppurativa: Need for a treat to target approach. Dermatological Reviews, 2022, 3, 123-125.	0.3	0
17	Suggestions for a New Clinical Classification Approach to Panniculitis Based on a Mayo Clinic Experience of 207 Cases. American Journal of Clinical Dermatology, 2022, 23, 739-746.	3.3	3
18	Measuring fatigue: a metaâ€review. International Journal of Dermatology, 2021, 60, 1053-1069.	0.5	26

#	ARTICLE	IF	CITATIONS
19	Trichotillomaniaâ€™ psychopathological correlates and associations with health-related quality of life in a large sample. <i>CNS Spectrums</i> , 2021, 26, 282-289.	0.7	5
20	Antidrug antibodies to tumour necrosis factor inhibitors in hidradenitis suppurativa: a systematic review. <i>British Journal of Dermatology</i> , 2021, 184, 555-557.	1.4	1
21	Ulcerative versus nonâ€™ulcerative panniculitis: is it time for a novel clinical approach to panniculitis?. <i>International Journal of Dermatology</i> , 2021, 60, 407-417.	0.5	4
22	Therapeutic Drug Monitoring in Patients with Suboptimal Response to Adalimumab for Hidradenitis Suppurativa: A Retrospective Case Series. <i>American Journal of Clinical Dermatology</i> , 2021, 22, 275-283.	3.3	8
23	A survey of clinicians regarding preferred severity assessment tools for hidradenitis suppurativa. <i>International Journal of Dermatology</i> , 2021, 60, e248-e251.	0.5	1
24	Race-Specific Prevalence of Hidradenitis Suppurativa. <i>Journal of Cutaneous Medicine and Surgery</i> , 2021, 25, 177-187.	0.6	33
25	Hidradenitis suppurativa and perceived stigmatization in a diverse Canadian clinic population: a pilot study. <i>British Journal of Dermatology</i> , 2021, 184, 570-571.	1.4	5
26	Hidradenitis Suppurativa Area and Severity Index Revised (HASIâ€™): psychometric property assessment*. <i>British Journal of Dermatology</i> , 2021, 184, 905-912.	1.4	18
27	A Systematic Review of Promising Therapeutic Targets in Hidradenitis Suppurativa: A Critical Evaluation of Mechanistic and Clinical Relevance. <i>Journal of Investigative Dermatology</i> , 2021, 141, 316-324.e2.	0.3	44
28	Identifying key components and therapeutic targets of the immune system in hidradenitis suppurativa with an emphasis on neutrophils. <i>British Journal of Dermatology</i> , 2021, 184, 1004-1013.	1.4	15
29	Use of an advanced collagen matrix dressing on patients with complex chronic lower extremity ulcers: A case series. <i>SAGE Open Medical Case Reports</i> , 2021, 9, 2050313X21110136.	0.2	0
30	Physician perspectives on complementary and alternative medicine in hidradenitis suppurativa. <i>Dermatologic Therapy</i> , 2021, 34, e14851.	0.8	3
31	Hidradenitis suppurativa odour and drainage scale: a novel method for evaluating odour and drainage in patients with hidradenitis suppurativa. <i>British Journal of Dermatology</i> , 2021, 184, 772-774.	1.4	4
32	Superficial Granulomatous Pyoderma Gangrenosum Involving the Face: A Case Series of Five Patients and a Review of the Literature. <i>Journal of Cutaneous Medicine and Surgery</i> , 2021, 25, 371-376.	0.6	5
33	Elevated Plasma Complement Proteins in Palmoplantar Pustulosis: A Potential Therapeutic Target. <i>Journal of Cutaneous Medicine and Surgery</i> , 2021, 25, 449-450.	0.6	1
34	Evaluation of barriers to therapeutic drug monitoring in the management of hidradenitis suppurativa. <i>Clinical and Experimental Dermatology</i> , 2021, 46, 936-938.	0.6	0
35	Global Harmonization of Morphological Definitions in Hidradenitis Suppurativa for a Proposed Glossary. <i>JAMA Dermatology</i> , 2021, 157, 449.	2.0	32
36	Coexistence of Hidradenitis Suppurativa and Steatocystoma Multiplex; Is It a New Variant of Hidradenitis Suppurativa?. <i>Journal of Cutaneous Medicine and Surgery</i> , 2021, 25, 120347542110101.	0.6	3

#	ARTICLE	IF	CITATIONS
37	Nemolizumab is associated with a rapid improvement in atopic dermatitis signs and symptoms: subpopulation (EASI-16) analysis of randomized phase 2B study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 1562-1568.	1.3	33
38	A response to Cannabinoids in Dermatologic Surgery: The added considerations of factors affecting tissue perfusion, wound healing, and modes of administration in safety and efficacy of cannabinoids. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, e385-e386.	0.6	1
39	Contact dermatitis: An important consideration in leg ulcers. <i>International Journal of Women's Dermatology</i> , 2021, 7, 298-303.	1.1	6
40	Provider perspectives on the management of hidradenitis suppurativa in pregnancy – A survey study. <i>International Journal of Women's Dermatology</i> , 2021, 7, 346-348.	1.1	3
41	Hidradenitis suppurativa in East and Southeast Asian populations: a systematic review and meta-analysis. <i>International Journal of Dermatology</i> , 2021, 60, e433-e439.	0.5	5
42	Cutaneous Manifestations of Diabetes. <i>Medical Clinics of North America</i> , 2021, 105, 681-697.	1.1	13
43	Laser Resurfacing Monotherapy for the Treatment of Actinic Keratosis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2021, 25, 120347542110275.	0.6	3
44	Challenging the association of hepatitis C and pyoderma gangrenosum. <i>British Journal of Dermatology</i> , 2021, 185, 1047-1048.	1.4	2
45	Efficacy and Safety of Adalimumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa. <i>JAMA Surgery</i> , 2021, 156, 1001.	2.2	62
46	A Systematic Review of Depression and Anxiety in Adults with Pyoderma Gangrenosum. <i>Advances in Skin and Wound Care</i> , 2021, 34, 432-436.	0.5	6
47	Real-world effectiveness of adalimumab in patients with moderate-to-severe hidradenitis suppurativa: the 1-year SOLACE study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 2431-2439.	1.3	13
48	An Abscess Is Not a Descriptive Term but an Entity With a Universally Accepted Definition – A Clarification on Semantics – Reply. <i>JAMA Dermatology</i> , 2021, 157, 1245-1246.	2.0	0
49	Is There a Role for Therapeutic Drug Monitoring in Patients with Hidradenitis Suppurativa on Tumor Necrosis Factor- $\alpha$ Inhibitors?. <i>American Journal of Clinical Dermatology</i> , 2021, 22, 139-147.	3.3	6
50	Development of a Patient-Reported Outcome Questionnaire to Assess Signs and Symptoms of Hidradenitis Suppurativa: The Hidradenitis Suppurativa Symptom Diary (HSSD). <i>Journal of the American Academy of Dermatology</i> , 2021, , .	0.6	0
51	Clinical manifestations and treatment outcomes of pyoderma gangrenosum following rituximab exposure: A systematic review. <i>Journal of the American Academy of Dermatology</i> , 2021, , .	0.6	1
52	Hidradenitis Suppurativa Area and Severity Index (HASI): a pilot study to develop a novel instrument to measure the physical signs of hidradenitis suppurativa. <i>British Journal of Dermatology</i> , 2020, 182, 240-242.	1.4	7
53	Exploring changes in placebo treatment arms in hidradenitis suppurativa randomized clinical trials: A systematic review. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 45-53.	0.6	13
54	Evaluating patients' unmet needs in hidradenitis suppurativa: Results from the Global Survey Of Impact and Healthcare Needs (VOICE) Project. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 366-376.	0.6	165

#	ARTICLE	IF	CITATIONS
55	The impact of hidradenitis suppurativa on work productivity and activity impairment. <i>British Journal of Dermatology</i> , 2020, 182, 1288-1290.	1.4	9
56	Role of the Complement Pathway in Inflammatory Skin Diseases: A Focus on Hidradenitis Suppurativa. <i>Journal of Investigative Dermatology</i> , 2020, 140, 531-536.e1.	0.3	28
57	Surgically resected hidradenitis suppurativa: a population-based cost analysis. <i>British Journal of Dermatology</i> , 2020, 182, 1300-1301.	1.4	3
58	Work impairment in a woman with severe hidradenitis suppurativa after delayed diagnosis: A call for action. <i>International Journal of Women's Dermatology</i> , 2020, 6, 327-328.	1.1	2
59	“Hidradenitis Suppurativa” is a Historical Term That Does Not Reflect the Current Understanding of Disease Pathogenesis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2020, 24, 644-645.	0.6	3
60	Inframammary Hidradenitis Suppurativa: An optimal surgical approach to a challenging region. <i>Breast Journal</i> , 2020, 26, 2312-2313.	0.4	1
61	Gender minority patients in dermatology clinical trials. <i>International Journal of Women's Dermatology</i> , 2020, 6, 438-439.	1.1	2
62	Pyoderma gangrenosum: proposed pathogenesis and current use of biologics with an emphasis on complement C5a inhibitor IFX-1. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 1179-1185.	1.9	16
63	The surgeon's perspective: a retrospective study of wide local excisions taken to healthy subcutaneous fat in the management of advanced hidradenitis suppurativa. <i>Canadian Journal of Surgery</i> , 2020, 63, E94-E99.	0.5	8
64	Trends in the management of hidradenitis suppurativa in the Middle East region: a systematic review. <i>International Journal of Dermatology</i> , 2020, 60, e440-e448.	0.5	2
65	Optimizing care for atopic dermatitis patients during the COVID-19 pandemic. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, e165-e167.	0.6	12
66	A Wound Care Specialist's Approach to Pyoderma Gangrenosum. <i>Advances in Wound Care</i> , 2020, 9, 686-694.	2.6	9
67	A case of sporotrichosis infection mimicking pyoderma gangrenosum and the role of tissue culture in diagnosis: A case report. <i>SAGE Open Medical Case Reports</i> , 2020, 8, 2050313X2091960.	0.2	3
68	Identification and evaluation of outcome measurement instruments in pyoderma gangrenosum: a systematic review*. <i>British Journal of Dermatology</i> , 2020, 183, 821-828.	1.4	12
69	Remote management of hidradenitis suppurativa in a pandemic era of COVID-19. <i>International Journal of Dermatology</i> , 2020, 59, e318-e320.	0.5	13
70	Complementary and Alternative Medicine Use in Patients With Hidradenitis Suppurativa. <i>JAMA Dermatology</i> , 2020, 156, 345.	2.0	16
71	Wound Healing in Pyoderma Gangrenosum. <i>Updates in Clinical Dermatology</i> , 2020, , 187-194.	0.1	0
72	Genotype-phenotype correlation in inherited hidradenitis suppurativa: one step forward, one step back. <i>British Journal of Dermatology</i> , 2019, 181, 443-444.	1.4	4

#	ARTICLE	IF	CITATIONS
73	Hemoglobin Levels and Serum C-Reactive Protein in Patients With Moderate to Severe Hidradenitis Suppurativa. <i>Journal of Cutaneous Medicine and Surgery</i> , 2019, 23, 501-506.	0.6	7
74	Genital Ulcer Disease: A Review of Pathogenesis and Clinical Features. <i>Journal of Cutaneous Medicine and Surgery</i> , 2019, 23, 624-634.	0.6	14
75	Scalp ulcers – differential diagnoses that should be sought!. <i>International Journal of Dermatology</i> , 2019, 58, 1283-1292.	0.5	2
76	Hidradenitis suppurativa and vasculitis: A case series and literature review of a rare association. <i>SAGE Open Medical Case Reports</i> , 2019, 7, 2050313X1988285.	0.2	4
77	Compression therapy for non-venous leg ulcers: Current viewpoint. <i>International Wound Journal</i> , 2019, 16, 1581-1586.	1.3	4
78	The role of anti-tumour necrosis factor in wound healing: A case report of refractory ulcerated necrobiosis lipoidica treated with adalimumab and review of the literature. <i>SAGE Open Medical Case Reports</i> , 2019, 7, 2050313X1988159.	0.2	6
79	New Perspectives on Topical Calcineurin Inhibitors: Role in Dermatology Today and Into the Future. <i>Journal of Cutaneous Medicine and Surgery</i> , 2019, 23, 3S-4S.	0.6	0
80	Specimen Collection for Translational Studies in Hidradenitis Suppurativa. <i>Scientific Reports</i> , 2019, 9, 12207.	1.6	10
81	<p>Martorell ulcer: chronic wound management and rehabilitation</p>. <i>Chronic Wound Care Management and Research</i> , 2019, Volume 6, 83-88.	0.4	1
82	Authors' Reply to Laneelle et al.: "Vascular Tests for Dermatologists". <i>American Journal of Clinical Dermatology</i> , 2019, 20, 737-738.	3.3	0
83	Hidradenitis Suppurativa: Comprehensive Review of Predisposing Genetic Mutations and Changes. <i>Journal of Cutaneous Medicine and Surgery</i> , 2019, 23, 519-527.	0.6	49
84	Depression and Anxiety in Adults With Hidradenitis Suppurativa. <i>JAMA Dermatology</i> , 2019, 155, 939.	2.0	100
85	Distribution of Self-reported Hidradenitis Suppurativa Age at Onset. <i>JAMA Dermatology</i> , 2019, 155, 971.	2.0	40
86	North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 91-101.	0.6	206
87	North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 76-90.	0.6	218
88	Vascular Tests for Dermatologists. <i>American Journal of Clinical Dermatology</i> , 2019, 20, 657-667.	3.3	6
89	Surfactants: Role in biofilm management and cellular behaviour. <i>International Wound Journal</i> , 2019, 16, 753-760.	1.3	38
90	A Vision for an Academic Career Mentorship Program for Canadian Dermatology Residents. <i>Journal of Cutaneous Medicine and Surgery</i> , 2019, 23, 123-124.	0.6	2

#	ARTICLE	IF	CITATIONS
91	Are Bacteria Infectious Pathogens in Hidradenitis Suppurativa? Debate at the Symposium for Hidradenitis Suppurativa Advances Meeting, November 2017. <i>Journal of Investigative Dermatology</i> , 2019, 139, 13-16.	0.3	26
92	Pyoderma gangrenosum and its impact on quality of life: a multicentre, prospective study. <i>British Journal of Dermatology</i> , 2019, 180, 672-673.	1.4	15
93	A 2017 update: Challenging the cosmetic procedural delay following oral isotretinoin therapy. <i>Journal of Cosmetic and Laser Therapy</i> , 2019, 21, 58-60.	0.3	4
94	Recent advances in managing and understanding pyoderma gangrenosum. <i>F1000Research</i> , 2019, 8, 2092.	0.8	38
95	Pyoderma Gangranosumâ€œLike Blastomycosis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2018, 22, 519-521.	0.6	2
96	Generalized Pustular Psoriasis Induced by Infliximab in a Patient With Inflammatory Bowel Disease. <i>Journal of Cutaneous Medicine and Surgery</i> , 2018, 22, 507-510.	0.6	20
97	Medical, Surgical, and Wound Care Management of Ulcerated Infantile Hemangiomas: A Systematic Review. <i>Journal of Cutaneous Medicine and Surgery</i> , 2018, 22, 495-504.	0.6	12
98	Quality of life and sexual health in patients with hidradenitis suppurativa. <i>International Journal of Women's Dermatology</i> , 2018, 4, 74-79.	1.1	52
99	The Contribution of Malodour in Quality of Life of Patients With Hidradenitis Suppurativa. <i>Journal of Cutaneous Medicine and Surgery</i> , 2018, 22, 166-174.	0.6	40
100	A Canadian Population-Based Cohort to the Study Cost and Burden of Surgically Resected Hidradenitis Suppurativa. <i>Journal of Cutaneous Medicine and Surgery</i> , 2018, 22, 312-317.	0.6	13
101	Optimal hidradenitis suppurativa topical treatment and wound care management: a revised algorithm. <i>Journal of Dermatological Treatment</i> , 2018, 29, 383-384.	1.1	12
102	Peristomal skin complications: what dermatologists need to know. <i>International Journal of Dermatology</i> , 2018, 57, 257-264.	0.5	36
103	Treatment for Livedoid Vasculopathy. <i>JAMA Dermatology</i> , 2018, 154, 193.	2.0	76
104	Angiosarcoma complicating lower leg elephantiasis in a male patient: An unusual clinical complication, case report and literature review. <i>SAGE Open Medical Case Reports</i> , 2018, 6, 2050313X1879634.	0.2	5
105	Vasculitisâ€œWhat Do We Have to Know? A Review of Literature. <i>International Journal of Lower Extremity Wounds</i> , 2018, 17, 218-226.	0.6	55
106	Integrating the skin and blood transcriptomes and serum proteome in hidradenitis suppurativa reveals complement dysregulation and a plasma cell signature. <i>PLoS ONE</i> , 2018, 13, e0203672.	1.1	71
107	Eruptive lentiginosis in resolving psoriatic plaques. <i>JAAD Case Reports</i> , 2018, 4, 924-929.	0.4	6
108	Inflammation: A Contributor to Depressive Comorbidity in Inflammatory Skin Disease. <i>Skin Pharmacology and Physiology</i> , 2018, 31, 246-251.	1.1	56

#	ARTICLE	IF	CITATIONS
109	Lipoedema is not lymphoedema: A review of current literature. <i>International Wound Journal</i> , 2018, 15, 921-928.	1.3	49
110	Livedoid Vasculopathy: an Updated Review. <i>Current Dermatology Reports</i> , 2018, 7, 125-135.	1.1	4
111	Lymphedema in patients with hidradenitis suppurativa: a systematic review of published literature. <i>International Journal of Dermatology</i> , 2018, 57, 1471-1480.	0.5	28
112	Pyoderma Gangrenosum: An Update on Pathophysiology, Diagnosis and Treatment. <i>American Journal of Clinical Dermatology</i> , 2017, 18, 355-372.	3.3	211
113	Development and validation of the International Hidradenitis Suppurativa Severity Score System ( ) Tj ETQq1 1 0.784314 rgBT /Overlo <i>Dermatology</i> , 2017, 177, 1401-1409.	1.4	301
114	Approach to the Management of Patients With Hidradenitis Suppurativa: A Consensus Document. <i>Journal of Cutaneous Medicine and Surgery</i> , 2017, 21, 513-524.	0.6	39
115	A systematic review of the relationship between glycemic control and necrobiosis lipoidica diabetorum in patients with diabetes mellitus. <i>International Journal of Dermatology</i> , 2017, 56, 1319-1327.	0.5	23
116	Pyoderma Gangrenosum: A Critical Appraisal. <i>Advances in Skin and Wound Care</i> , 2017, 30, 534-542.	0.5	13
117	Topical management and wound care approaches for hidradenitis suppurativa. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2017, 36, 58-61.	1.6	6
118	Major gaps in understanding and treatment of hidradenitis suppurativa. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2017, 36, 86-92.	1.6	22
119	Wound-Related Allergic/Irritant Contact Dermatitis. <i>Advances in Skin and Wound Care</i> , 2016, 29, 278-286.	0.5	31
120	Radiodermatitis: A Review of Our Current Understanding. <i>American Journal of Clinical Dermatology</i> , 2016, 17, 277-292.	3.3	218
121	The Point Prevalence of Malignancy in a Wound Clinic. <i>International Journal of Lower Extremity Wounds</i> , 2016, 15, 58-62.	0.6	7
122	Critical Evaluation of Delayed Healing of Venous Leg Ulcers: A Retrospective Analysis in Canadian Patients. <i>American Journal of Clinical Dermatology</i> , 2016, 17, 539-544.	3.3	7
123	Discussion. <i>Plastic and Reconstructive Surgery</i> , 2016, 138, 230S-231S.	0.7	5
124	An unusual presentation of Vilanova disease (erythema nodosum migrans) with superficial histologic changes. <i>JAAD Case Reports</i> , 2016, 2, 41-43.	0.4	2
125	Clinical Features and Patient Outcomes of Hidradenitis Suppurativa. <i>Journal of Cutaneous Medicine and Surgery</i> , 2016, 20, 52-57.	0.6	19
126	What's new: Management of venous leg ulcers. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 627-640.	0.6	91



#	ARTICLE	IF	CITATIONS
127	What's new: Management of venous leg ulcers. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 643-664.	0.6	85
128	Amantadine-Induced Livedo Racemosa. <i>International Journal of Lower Extremity Wounds</i> , 2016, 15, 78-81.	0.6	6
129	Livedoid vasculopathy and high levels of lipoprotein (a): response to danazol. <i>Dermatologic Therapy</i> , 2015, 28, 248-253.	0.8	21
130	A Review of the Diagnosis and Management of Erythroderma (Generalized Red Skin). <i>Advances in Skin and Wound Care</i> , 2015, 28, 228-236.	0.5	53
131	Hidradenitis Suppurativa. <i>Advances in Skin and Wound Care</i> , 2015, 28, 325-332.	0.5	15
132	Hemoglobinopathies and Leg Ulcers. <i>International Journal of Lower Extremity Wounds</i> , 2015, 14, 213-216.	0.6	10
133	Reply to letter to editor: Audible handheld Doppler ultrasound determines reliable and inexpensive exclusion of significant peripheral arterial disease. <i>Vascular</i> , 2015, 23, 445-446.	0.4	0
134	Quality-of-Life Impairment in Patients with Hidradenitis Suppurativa: A Canadian Study. <i>American Journal of Clinical Dermatology</i> , 2015, 16, 61-65.	3.3	128
135	Audible handheld Doppler ultrasound determines reliable and inexpensive exclusion of significant peripheral arterial disease. <i>Vascular</i> , 2015, 23, 622-629.	0.4	31
136	Necrobiosis Lipoidica. <i>Dermatologic Clinics</i> , 2015, 33, 343-360.	1.0	63
137	Epidermolysis Bullosa Pruriginosa. <i>International Journal of Lower Extremity Wounds</i> , 2015, 14, 196-199.	0.6	13
138	Recurrence of hidradenitis suppurativa after surgical management: A systematic review and meta-analysis. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, S70-S77.	0.6	148
139	Propylthiouracil-Induced Vasculitis With Antineutrophil Cytoplasmic Antibody. <i>International Journal of Lower Extremity Wounds</i> , 2015, 14, 187-191.	0.6	11
140	Local wound care and topical management of hidradenitis suppurativa. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, S55-S61.	0.6	29
141	Hidradenitis suppurativa: Demystifying a chronic and debilitating disease. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, S1-S2.	0.6	10
142	Reply to Frane: Epidermolysis Bullosa Pruriginosa: A Systematic Review Exploring Genotypeâ€œPhenotype Correlation. <i>American Journal of Clinical Dermatology</i> , 2015, 16, 339-339.	3.3	1
143	Lipedema. <i>International Journal of Lower Extremity Wounds</i> , 2015, 14, 262-267.	0.6	51
144	Atrophie Blanche. <i>Advances in Skin and Wound Care</i> , 2014, 27, 518-524.	0.5	17

#	ARTICLE	IF	CITATIONS
145	Diabetic foot ulcers. Journal of the American Academy of Dermatology, 2014, 70, 21.e1-21.e24.	0.6	161
146	Diabetic foot ulcers. Journal of the American Academy of Dermatology, 2014, 70, 1.e1-1.e18.	0.6	230
147	Quality-of-life impairment in patients with livedoid vasculopathy. Journal of the American Academy of Dermatology, 2014, 71, 1024-1026.	0.6	35
148	Neutrophilic Dermatoses: An Update. American Journal of Clinical Dermatology, 2014, 15, 413-423.	3.3	63
149	Elevated Levels of Coagulation Factor VIII in Patients With Venous Leg Ulcers. International Journal of Lower Extremity Wounds, 2014, 13, 130-134.	0.6	11
150	Update on necrobiosis lipoidica: A review of etiology, diagnosis, and treatment options. Journal of the American Academy of Dermatology, 2013, 69, 783-791.	0.6	153
151	Livedoid vasculopathy: An in-depth analysis using a modified Delphi approach. Journal of the American Academy of Dermatology, 2013, 69, 1033-1042.e1.	0.6	94
152	A Review of the Clinical Variants and the Management of Psoriasis. Advances in Skin and Wound Care, 2013, 26, 271-284.	0.5	31
153	New advances in compression therapy for venous leg ulcers. Surgical Technology International, 2013, 23, 61-8.	0.1	14
154	Necrobiotic Xanthogranuloma as an Unusual Cause of Refractive Chronic Bilateral Leg Ulceration. International Journal of Lower Extremity Wounds, 2012, 11, 293-295.	0.6	4
155	Martorell Hypertensive Ischemic Leg Ulcer. Advances in Skin and Wound Care, 2012, 25, 563-572.	0.5	31
156	Diagnosis and Treatment of Hand Dermatitis. Advances in Skin and Wound Care, 2012, 25, 371-380.	0.5	14
157	Corticosteroid-induced hyperglycemia is increased 10-fold in patients with pemphigus. International Journal of Dermatology, 2012, 51, 1248-1252.	0.5	12
158	When and How to Perform a Biopsy on a Chronic Wound. Advances in Skin and Wound Care, 2010, 23, 132-140.	0.5	17
159	Common foot examination features of 247 Iranian patients with diabetes. International Wound Journal, 2009, 6, 117-122.	1.3	17
160	Contact Allergens in Persons With Leg Ulcers: A Canadian Study in Contact Sensitization. International Journal of Lower Extremity Wounds, 2008, 7, 120-125.	0.6	36
161	Guidance on COVID-19 Vaccination in Hidradenitis Suppurativa Patients: A Modified Delphi Consensus of Experts. Skin Appendage Disorders, 0, , 1-4.	0.5	1